APELOA Pharmaceutical Co., Ltd. (http://www.apeloa.com) a public listed pharmaceutical company in China, and a member of Hengdian Group, devotes itself to provide efficient, flexible and high-quality solutions for pharmaceutical products to global needs.

APELOA is committed to the research & development, production, and sales of pharmaceutical intermediates, APIs, and finished dosages. In addition, Apeloa offers one-stop CDMO service to global pharmaceutical companies.

The company owns 7 production sites (5 chemical synthesis & 2 biological fermentation) for API/Intermediates and CDMO, and 3 productions sites for FDF. Apeloa has an excellent track record with regulatory authorities including US FDA, EDQM, PMDA, NMPA.

In the recent report from the MIIT (Ministry of Industry and Information Technology of the People’s Republic of China), APELOA ranked 49th from TOP 100 Chinese Pharmaceutical Companies, also ranked as 2nd for API exporter. In the other hand, APELOA ranked 21st in “China's top 100 pharmaceutical industry in 2019” List which published by Minet, a rating platform that sponsored by NMPA.

APELOA Shanghai R&D center established in 2018, is located in Shanghai Pudong Wisecity Park, with 6700 m² R&D footprint expected to hold 260 chemists. The R&D center aims to accelerate drug discovery in CDMO part.